Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

NCT04676724 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B

Interventions

DRUG: GSK3228836
DRUG: PegIFN
DRUG: NA therapy

Sponsor

GlaxoSmithKline